Advertisement
Singapore markets closed
  • Straits Times Index

    3,292.93
    -3.96 (-0.12%)
     
  • Nikkei

    38,236.07
    -37.98 (-0.10%)
     
  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Bitcoin USD

    63,251.86
    +358.54 (+0.57%)
     
  • CMC Crypto 200

    1,309.64
    +32.66 (+2.56%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • Dow

    38,675.68
    +450.02 (+1.18%)
     
  • Nasdaq

    16,156.33
    +315.37 (+1.99%)
     
  • Gold

    2,310.10
    +0.50 (+0.02%)
     
  • Crude Oil

    77.99
    -0.96 (-1.22%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • FTSE Bursa Malaysia

    1,589.59
    +9.29 (+0.59%)
     
  • Jakarta Composite Index

    7,134.72
    +17.30 (+0.24%)
     
  • PSE Index

    6,615.55
    -31.00 (-0.47%)
     

C4X Discovery Holdings plc (LON:C4XD) Is About To Turn The Corner

C4X Discovery Holdings plc (LON:C4XD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The UK£21m market-cap company announced a latest loss of UK£11m on 31 July 2023 for its most recent financial year result. Many investors are wondering about the rate at which C4X Discovery Holdings will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for C4X Discovery Holdings

According to the 2 industry analysts covering C4X Discovery Holdings, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2023, before generating positive profits of UK£5.8m in 2024. The company is therefore projected to breakeven around a year from now or less! How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2024? Working backwards from analyst estimates, it turns out that they expect the company to grow -13% year-on-year, on average,

earnings-per-share-growth
earnings-per-share-growth

We're not going to go through company-specific developments for C4X Discovery Holdings given that this is a high-level summary, but, bear in mind that generally a life science company has lumpy cash flows which are contingent on the product and stage of development the company is in. This means that a low or volatile growth rate in the near future is not unusual, especially if the company is currently in an investment period.

ADVERTISEMENT

Before we wrap up, there’s one aspect worth mentioning. C4X Discovery Holdings currently has no debt on its balance sheet, which is quite unusual for a cash-burning life science company, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are key fundamentals of C4X Discovery Holdings which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at C4X Discovery Holdings, take a look at C4X Discovery Holdings' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at:

  1. Historical Track Record: What has C4X Discovery Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on C4X Discovery Holdings' board and the CEO’s background.

  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.